MYC addiction in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 905-906

  Rossi, Davide ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; MYC PROTEIN; NOTCH RECEPTOR;

CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; GENE DELETION; HODGKIN DISEASE; HUMAN; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MOLECULAR PATHOLOGY; NONHUMAN; NOTE; ONCOGENE MYC; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84876220024     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.755179     Document Type: Note

References (15)

1. Dang CV. MYC on the path to cancer. Cell 2012;149:22-35.
2. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 2011;29:1835-1843.
3. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 6q24.1 inf uence chronic lymphocytic leukemia risk. Nat Genet 2010;42:132-136.
4. Zhang W, Kater AP, Widhopf GF 2nd, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) inf uence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010;107:18956-18960.
5. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
6. Krysov S, Dias S, Paterson A, et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012;119:170-179.
7. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
8. Huh YO, Lin KI, Vega F, et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol 2008;142:36-44.
9. Edelmann J, Holzmann K, Miller F, et al. High-resolution genomic prof ling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012;120:4783-4794.
10. Brown JR, Hanna M, Tesar B, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 3791-3802.
11. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391-3401.
12. Cascón A, Robledo M. MAX and MYC: a heritable breakup. Cancer Res 2012;72:3119-3124.
13. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identif es recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
14. de Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54; 1087-1090.
15. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.